Tesamorelin Beyond HIV: Abdominal Obesity, Healthy Men, Older Adults and the Generalisability Problem

RESEARCH · TESAMORELIN · BEYOND HIV

Tesamorelin Beyond HIV: Abdominal Obesity, Healthy Men, Older Adults and the Generalisability Problem

PurixLab’s Tesamorelin 5mg is a research vial of the stabilised GHRH(1-44) analogue. Our earlier articles cover a research overview, visceral fat and liver fat and glucose, insulin sensitivity and HbA1c. Almost all of that work was done in people with HIV. This article looks at the much smaller body of research outside HIV-associated lipodystrophy: abdominal obesity, healthy men, older adults with and without mild cognitive impairment, type 2 diabetes and preclinical safety work. These are published findings from clinical research under medical supervision and from animal studies; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Why look beyond HIV?

Tesamorelin was developed and approved for one narrow indication, so most trial participants share a specific clinical background. Researchers outside that setting have asked a different question: does stimulating the body’s own growth hormone (GH) release behave the same way where GH secretion is reduced for other reasons, such as abdominal obesity or ageing? A 2013 review of GH in ageing men described this rationale, noting that GH and IGF-1 fall with age and that controlled GH supplementation studies in older men increased lean mass by about 2 kg, with little evidence of better strength, walking speed or quality of life. The same review highlighted the GHRH-agonist approach as one that restores normal GH pulsatility, and observed that women appear more resistant to GH treatment [1]. The non-HIV literature on tesamorelin itself, however, is thin, and much of it comes from a small number of research groups.

Abdominal obesity without HIV

The clearest non-HIV trial comes from Makimura, Grinspoon and colleagues. They enrolled 60 abdominally obese adults whose GH secretion was reduced on stimulation testing, and randomised them to tesamorelin or placebo for 12 months in a double-blind design [2]. Results compared with placebo:

  • Visceral fat. Visceral adipose tissue measured by CT fell, with a treatment effect of -35 cm² (P = 0.003), while abdominal subcutaneous fat did not change significantly (P = 0.40).
  • Vascular and lipid markers. Carotid intima-media thickness (treatment effect -0.04 mm), log C-reactive protein and triglycerides (-37 mg/dl) also improved.
  • IGF-I and glucose. IGF-I rose by 92 μg/liter relative to placebo, with no changes in fasting glucose, 2-hour glucose or glycated haemoglobin.
  • Safety. There were no serious adverse events and no difference in adverse events between groups.

A secondary analysis of 39 participants from the same programme used phosphorus magnetic resonance spectroscopy to measure phosphocreatine recovery after submaximal exercise, a marker linked to mitochondrial function. IGF-I rose by 102.9 μg/L with tesamorelin versus 22.8 μg/L with placebo, and larger IGF-I increases correlated with faster recovery (R = 0.56; R = 0.71 among tesamorelin-treated participants only). The authors described this as suggestive of improved mitochondrial function [3]. This is a correlation within a small sample, not a direct treatment comparison on the mitochondrial outcome.

Short-term studies in healthy and overweight men

Before the year-long trial, the same group ran two-week mechanistic studies. In 13 healthy men with a mean age of 45 and mean BMI of 27.3 kg/m², tesamorelin increased mean overnight GH and basal GH secretion, and IGF-I rose by 181 μg/liter. Neither fasting glucose nor insulin-stimulated glucose uptake measured by clamp changed significantly [4]. In 13 men with BMI between 20 and 35 kg/m², baseline total adiponectin tracked closely with GH peak area (r = +0.73), but two weeks of tesamorelin did not change total or high-molecular-weight adiponectin, with similar results in the overweight and obese subgroup [5]. A further study in healthy volunteers used two crossover studies to test drug interactions and found that tesamorelin had minimal, if any, effect on CYP3A activity [6].

Older adults and mild cognitive impairment

The largest non-HIV trial was about the brain rather than body fat; our cognition article covers it in more detail, so only the points relevant to generalisability are summarised here. Baker and colleagues randomised 152 adults aged 55 to 87, 66 of them with mild cognitive impairment (MCI), to tesamorelin or placebo for 20 weeks; 137 completed the study [7].

  • Cognition. The intent-to-treat analysis showed a favourable effect on a cognitive composite (P = .03), similar in adults with MCI and healthy older adults, driven by executive function.
  • Hormones and body composition. IGF-1 rose by 117% but stayed within the physiological range, and percent body fat fell by 7.4%.
  • Insulin and adverse events. Fasting insulin rose by 35% in adults with MCI, still within the normal range, but not in healthy adults. Adverse events were mild but reported by 68% of the tesamorelin group versus 36% on placebo.

A spectroscopy substudy of 30 participants reported higher brain GABA after 20 weeks, but no significant associations between neurochemical and cognitive changes [8]. A later double-blind pilot in 22 adults treated for 10 weeks found no significant treatment-related changes in body composition, sleep, physical performance, glucose tolerance, cognition or brain imaging; only exploratory machine-learning analyses flagged possible regional brain differences [9].

Type 2 diabetes

Glucose is covered in our earlier article, so briefly: in a 12-week randomised trial of 53 people with type 2 diabetes, tesamorelin did not alter the relative insulin response, fasting glucose or HbA1c compared with placebo, and no participant withdrew because of lost diabetes control. Total and non-HDL cholesterol fell by 0.3 mmol/L in the higher tesamorelin arm [10]. This is a safety-focused study, not evidence of benefit in diabetes.

Preclinical safety

The non-clinical programme for TH9507, as tesamorelin was coded, showed resistance to dipeptidyl aminopeptidase-IV and longer plasma persistence than natural GHRH, with GH and IGF-1 increases in pigs, rats and dogs. In toxicity studies lasting up to 4 months, dogs showed a stronger anabolic effect and reversible liver and kidney findings, anaemia and organ weight changes, which the authors attributed to sustained supraphysiological GH and IGF-1. The elimination half-life in dogs ranged from 21 to 45 min [11].

Limits of the evidence and open questions

  • Few trials, small samples. Outside HIV, the controlled evidence rests on a handful of randomised trials of 22 to 152 participants, plus two-week studies of 13 men [2,7,9,4].
  • Selected populations. The obesity trial enrolled only people with reduced GH secretion, so its findings may not apply to people with obesity generally [2].
  • Surrogate endpoints. Visceral fat, intima-media thickness, IGF-I, phosphocreatine kinetics and brain metabolites are markers, not clinical outcomes, and the mitochondrial and neurochemical findings are correlational [3,8].
  • Inconsistent cognitive results. The 20-week cognitive signal was not reproduced in the smaller 10-week pilot, which reported no significant direct effects [7,9].
  • Adverse events and insulin. More adverse events and a rise in fasting insulin among adults with MCI mean that tolerability cannot be assumed to transfer between populations [7].
  • No long-term data. None of these studies ran longer than 12 months, and the dog findings show that sustained high GH and IGF-1 exposure has consequences [11].
  • The gap with unregulated use. Recent reviews note that tesamorelin appears in online self-administration protocols and “research compound” markets for physique or performance goals that have no regulatory approval, and that rigorous human safety data for such uses are scarce [12,13]. The trials above do not address those uses.

Open questions include whether visceral fat findings in GH-reduced obesity hold in broader groups, whether any cognitive effect is reproducible, and how women, who appear more resistant to GH treatment, respond to GHRH-based approaches [1].

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-55. PubMed 24054930 · PMC3940699 · doi:10.1016/j.beem.2013.05.003
  2. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. PubMed 23015655 · PMC3513535 · doi:10.1210/jc.2012-2794
  3. Makimura H, Murphy CA, Feldpausch MN, et al. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014;99(1):338-43. PubMed 24178787 · PMC3879673 · doi:10.1210/jc.2013-3436
  4. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. PubMed 20943777 · PMC3038486 · doi:10.1210/jc.2010-1587
  5. Makimura H, Stanley TL, Chen CY, et al. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor. Growth Horm IGF Res. 2011;21(3):155-9. PubMed 21531600 · PMC3112279 · doi:10.1016/j.ghir.2011.03.009
  6. Teng S, Potvin D, Mamputu JC, et al. Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers. Clin Pharmacol Drug Dev. 2013;2(3):237-45. PubMed 27121785 · doi:10.1002/cpdd.27
  7. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PubMed 22869065 · PMC3764914 · doi:10.1001/archneurol.2012.1970
  8. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-90. PubMed 23689947 · PMC3764915 · doi:10.1001/jamaneurol.2013.1425
  9. Stewart CE, French KP, Wright TJ, et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci. 2026;44:100616. PubMed 42382101 · PMC13316082 · doi:10.1016/j.ensci.2026.100616
  10. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PubMed 28617838 · PMC5472315 · doi:10.1371/journal.pone.0179538
  11. Ferdinandi ES, Brazeau P, High K, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611 · doi:10.1111/j.1742-7843.2007.00008.x
  12. Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176 · PMC13322892 · doi:10.3389/fendo.2026.1822475
  13. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639 · doi:10.1007/s40279-026-02437-0

Leave a Comment

Your email address will not be published. Required fields are marked *